{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T01:26:29.896727+00:00","company":{"ticker":"ADMA","cik":1368514,"company_name":"ADMA BIOLOGICS, INC."},"pagination":{"limit":100,"returned":13,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"shareholder_vote","fact_key":"a335a5d8fbb0276567b1892e3679f4d1e1b8d129","cik":1368514,"ticker":"ADMA","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2026-06-02T20:05:29+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-02","outcome":"passed","proposal_text":"Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"23,040,875","subject":null,"votes_abstain":"326,116","votes_against":"7,730,690","votes_for":"168,169,866","votes_withheld":null}]},"claim":"ADMA BIOLOGICS, INC. shareholders approved Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers at the 2026-06-02 meeting.","evidence_excerpt":"Proposal No. 3 — Approval of the Say-on-Pay Proposal The vote with respect to the approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers was as follows: For Against Abstain Broker Non-Votes 168,169,866 Shares 7,730,690 Shares 326,116 Shares 23,040,875 Shares","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-26-023705","anchor_url":"https://secwatch.observer/filing/0001140361-26-023705#claim-a335a5d8fbb0276567b1892e3679f4d1e1b8d129","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036126023705/0001140361-26-023705-index.htm"},{"fact_type":"shareholder_vote","fact_key":"fd165b3e5f30426ffb18a59524f1266fcafaf67d","cik":1368514,"ticker":"ADMA","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2026-06-02T20:05:29+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-02","outcome":"passed","proposal_text":"Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"283,451","votes_against":"329,056","votes_for":"198,655,040","votes_withheld":null}]},"claim":"ADMA BIOLOGICS, INC. shareholders approved Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-02 meeting.","evidence_excerpt":"Proposal No. 2 — Ratification of the Appointment of Independent Registered Public Accounting Firm The vote with respect to the ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was as follows: For Against Abstain 198,655,040 Shares 329,056 Shares 283,451 Shares","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-26-023705","anchor_url":"https://secwatch.observer/filing/0001140361-26-023705#claim-fd165b3e5f30426ffb18a59524f1266fcafaf67d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036126023705/0001140361-26-023705-index.htm"},{"fact_type":"shareholder_vote","fact_key":"1dfeb25914d1bc40d046db79e0d271e4a9e467bb","cik":1368514,"ticker":"ADMA","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2026-06-02T20:05:29+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-02","outcome":"passed","proposal_text":"Election of two nominees to serve as Class I directors until the Company's 2029 Annual Meeting of Stockholders and until such director's successor is duly elected and qualified, or such director's earlier resignation, removal or death","proposal_type":"director_election","results":[{"broker_non_votes":"23,040,875","subject":"Alison C. Finger","votes_abstain":null,"votes_against":null,"votes_for":"156,849,830","votes_withheld":"19,376,842"},{"broker_non_votes":"23,040,875","subject":"Eduardo Rene Salas","votes_abstain":null,"votes_against":null,"votes_for":"171,947,523","votes_withheld":"4,279,149"}]},"claim":"ADMA BIOLOGICS, INC. shareholders approved Election of two nominees to serve as Class I directors until the Company's 2029 Annual Meeting of Stockholders and until such director's successor is duly elected and qualified, or such director's earlier resignation, removal or death at the 2026-06-02 meeting.","evidence_excerpt":"Proposal No. 1 — Election of the Class I Directors The vote with respect to the election of each of the directors was as follows: Nominee For Withheld Broker Non-Votes Alison C. Finger 156,849,830 19,376,842 23,040,875 Eduardo Rene Salas 171,947,523 Shares 4,279,149 Shares 23,040,875 Shares","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-26-023705","anchor_url":"https://secwatch.observer/filing/0001140361-26-023705#claim-1dfeb25914d1bc40d046db79e0d271e4a9e467bb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036126023705/0001140361-26-023705-index.htm"},{"fact_type":"earnings_release","fact_key":"6b7bea8aced1778457c2cd10cbcefdef5f833437","cik":1368514,"ticker":"ADMA","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2026-05-06T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"initiated","item_codes_triggered":["2.02"],"net_income_text":"$170 million to $200 million","period_text":"FY 2026","report_date":"2026-05-06","result_type":"guidance_update","revenue_text":"$530 million to $560 million"},"claim":"ADMA BIOLOGICS, INC. reported FY 2026 results: revenue $530 million to $560 million, net income $170 million to $200 million. Guidance initiated.","evidence_excerpt":"FY 2026 total revenue expected to be $530 million to $560 million • FY 2026 Adjusted Net Income expected to be $170 million to $200 million • FY 2026 Adjusted EBITDA expected to be $265 million to $300 million","confidence":0.85,"filing_url":"https://secwatch.observer/filing/0001140361-26-019295","anchor_url":"https://secwatch.observer/filing/0001140361-26-019295#claim-6b7bea8aced1778457c2cd10cbcefdef5f833437","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036126019295/0001140361-26-019295-index.htm"},{"fact_type":"earnings_release","fact_key":"42c4759ff59dbcab36661a81448bebd6845c98c1","cik":1368514,"ticker":"ADMA","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2026-05-06T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Adjusted Net Income (1) of $40.7 Million","period_text":"three months ended March 31, 2026","report_date":"2026-05-06","result_type":"reported_results","revenue_text":"$114.5 Million"},"claim":"ADMA BIOLOGICS, INC. reported three months ended March 31, 2026 results: revenue $114.5 Million, net income Adjusted Net Income (1) of $40.7 Million.","evidence_excerpt":"---\n\nEX-99.1 2 ef20072554_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update 1Q 2026 Total Revenue of $114.5 Million, Flat Year-Over-Year 1Q 2026 ASCENIV Revenue +28% Year-Over-Year; BIVIGAM Revenue -54% Year-Over-Year 1Q 2026 Adjusted Net Income (1) of $40.7 Million, 22% Year-Over-Year Growth","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-26-019295","anchor_url":"https://secwatch.observer/filing/0001140361-26-019295#claim-42c4759ff59dbcab36661a81448bebd6845c98c1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036126019295/0001140361-26-019295-index.htm"},{"fact_type":"debt_financing","fact_key":"780258111d7065885275191180df0211cc6827a2","cik":1368514,"ticker":"ADMA","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2025-08-06T23:59:59+00:00","payload":{"counterparty":"JPMorgan Chase Bank, N.A.","effective_date":"2025-08-05","event":"incurrence","instrument_type":"revolving_credit","interest_rate_text":"150 basis points to 200 basis points over the alternate base rate and 250 basis","item_codes_triggered":["2.03"],"maturity_text":"August 5, 2028","principal_text":"$225 million"},"claim":"ADMA BIOLOGICS, INC. incurred revolving credit of $225 million with JPMorgan Chase Bank, N.A. at 150 basis points to 200 basis points over the alternate base rate and 250 basis maturing August 5, 2028.","evidence_excerpt":"The Credit Agreement provides for $300 million of senior secured credit facilities, consisting of (a) a term loan in the aggregate principal amount of $75 million (the \"Term Loan Facility\") and (b) a revolving credit facility in the aggregate principal amount of $225 million (the \"Revolving Facility\").","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-25-029143","anchor_url":"https://secwatch.observer/filing/0001140361-25-029143#claim-780258111d7065885275191180df0211cc6827a2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125029143/0001140361-25-029143-index.htm"},{"fact_type":"debt_financing","fact_key":"65d79af5e31b317cc6c92c7aaa937d772468ff0a","cik":1368514,"ticker":"ADMA","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2025-08-06T23:59:59+00:00","payload":{"counterparty":"JPMorgan Chase Bank, N.A.","effective_date":"2025-08-05","event":"incurrence","instrument_type":"term_loan","interest_rate_text":"150 basis points to 200 basis points over the alternate base rate and 250 basis","item_codes_triggered":["2.03"],"maturity_text":"August 5, 2028","principal_text":"$75 million"},"claim":"ADMA BIOLOGICS, INC. incurred term loan of $75 million with JPMorgan Chase Bank, N.A. at 150 basis points to 200 basis points over the alternate base rate and 250 basis maturing August 5, 2028.","evidence_excerpt":"The Credit Agreement provides for $300 million of senior secured credit facilities, consisting of (a) a term loan in the aggregate principal amount of $75 million (the \"Term Loan Facility\") and (b) a revolving credit facility in the aggregate principal amount of $225 million (the \"Revolving Facility\").","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-25-029143","anchor_url":"https://secwatch.observer/filing/0001140361-25-029143#claim-65d79af5e31b317cc6c92c7aaa937d772468ff0a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125029143/0001140361-25-029143-index.htm"},{"fact_type":"debt_financing","fact_key":"b269ccc296b5b23e792f4e75018f44f45ae342c8","cik":1368514,"ticker":"ADMA","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2025-08-06T23:59:59+00:00","payload":{"counterparty":"JPMorgan Chase Bank, N.A.","effective_date":"2025-08-05","event":"incurrence","instrument_type":"credit_facility","interest_rate_text":"150 basis points to 200 basis points over the alternate base rate and 250 basis","item_codes_triggered":["2.03"],"maturity_text":"August 5, 2028","principal_text":"$300 million"},"claim":"ADMA BIOLOGICS, INC. incurred credit facility of $300 million with JPMorgan Chase Bank, N.A. at 150 basis points to 200 basis points over the alternate base rate and 250 basis maturing August 5, 2028.","evidence_excerpt":"into a Credit Agreement\n (the “Credit Agreement”), with the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent. The Credit Agreement provides for $300 million of senior secured credit facilities, consisting of (a) a term loan in the aggregate\n principal amount of $75 million (the “Term Loan Facility”) and (b) a revolving credit","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-25-029143","anchor_url":"https://secwatch.observer/filing/0001140361-25-029143#claim-b269ccc296b5b23e792f4e75018f44f45ae342c8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125029143/0001140361-25-029143-index.htm"},{"fact_type":"executive_change","fact_key":"8c1b2ad927","cik":1368514,"ticker":"ADMA","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2025-01-02T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-12-30","interim":false,"role":"Class I Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Eduardo Rene Salas was appointed as Class I Director at ADMA BIOLOGICS, INC..","evidence_excerpt":"On December 30, 2024, the Board of Directors (the “Board”) of ADMA Biologics, Inc. (the “Company”) appointed Eduardo Rene Salas to serve on the Board as a Class I director with a term expiring at the Company’s 2026 annual meeting of stockholders.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-25-000073","anchor_url":"https://secwatch.observer/filing/0001140361-25-000073#claim-8c1b2ad927","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125000073/0001140361-25-000073-index.htm"},{"fact_type":"executive_change","fact_key":"1c94ec53f0","cik":1368514,"ticker":"ADMA","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2024-11-21T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-11-19","interim":false,"role":"member of the Board of Directors","role_category":"director","successor_name":null,"successor_named":false},"claim":"Bryant E. Fong resigned as member of the Board of Directors at ADMA BIOLOGICS, INC..","evidence_excerpt":"On November 19, 2024, Bryant E. Fong notified ADMA Biologics, Inc. (the “Company”) that he resigned, effective immediately, as a member of the Company’s Board of Directors (the “Board”) and any committees of the Board in order to devote more time to his roles as Managing Director of Biomark Capital Fund and as Partner and Co-Portfolio Manager of Stonepine Capital Management.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-24-047487","anchor_url":"https://secwatch.observer/filing/0001140361-24-047487#claim-1c94ec53f0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124047487/0001140361-24-047487-index.htm"},{"fact_type":"executive_change","fact_key":"a04bddc714","cik":1368514,"ticker":"ADMA","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2024-07-26T23:59:59+00:00","payload":{"action":"promoted","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2024-07-24","interim":false,"role":"Chief Financial Officer and Treasurer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Brad Tade changed role as Chief Financial Officer and Treasurer at ADMA BIOLOGICS, INC..","evidence_excerpt":"Brad Tade, former Vice President, Financial Operations of ADMA Biologics, Inc. (the \"Company\"), was promoted to Chief Financial Officer and Treasurer of the Company","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-24-034440","anchor_url":"https://secwatch.observer/filing/0001140361-24-034440#claim-a04bddc714","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124034440/0001140361-24-034440-index.htm"},{"fact_type":"earnings_release","fact_key":"3bcfb2f36e086bbc778e55c23d5fc6347f35a466","cik":1368514,"ticker":"ADMA","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2024-05-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":"$17.8 Million","period_text":"three months ended March 31, 2024","report_date":"2024-05-09","result_type":"reported_results","revenue_text":"$81.9 Million"},"claim":"ADMA BIOLOGICS, INC. reported three months ended March 31, 2024 results: revenue $81.9 Million, net income $17.8 Million. Guidance raised.","evidence_excerpt":"ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update 1Q 2024 Total Revenue of $81.9 Million, a 44% Increase Y-o-Y 1Q 2024 GAAP Net Income of $17.8 Million, a $24.6 Million Increase Y-o-Y","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-24-025173","anchor_url":"https://secwatch.observer/filing/0001140361-24-025173#claim-3bcfb2f36e086bbc778e55c23d5fc6347f35a466","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124025173/0001140361-24-025173-index.htm"},{"fact_type":"executive_change","fact_key":"e6950a83cf","cik":1368514,"ticker":"ADMA","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2024-04-02T23:59:59+00:00","payload":{"action":"promoted","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2024-04-01","interim":false,"role":"Chief Operating Officer and Senior Vice President, Compliance","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Kaitlin Kestenberg changed role as Chief Operating Officer and Senior Vice President, Compliance at ADMA BIOLOGICS, INC..","evidence_excerpt":"Effective April 1, 2024 (the “Effective Date”), Kaitlin Kestenberg, former Senior Vice President, Compliance & Project Operations of ADMA Biologics, Inc. (the “Company”), was promoted to Chief Operating Officer and Senior Vice President, Compliance of the Company","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-24-017331","anchor_url":"https://secwatch.observer/filing/0001140361-24-017331#claim-e6950a83cf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036124017331/0001140361-24-017331-index.htm"}]}